What is the background of this study?
“High-risk (R-ISS stage III) newly diagnosed multiple myeloma (NDMM) has a poor prognosis with a median progression-free survival of 29 months. According to Dr. Antonio Palumbo, this highlights the need for novel disease-targeting approaches (Palumbo A, et al. J Clin Oncol 2015;33:2863-2869). Ide-cel, a BCMA-directed CAR-T cell therapy, demonstrated deep, durable responses in heavily pretreated patients with relapsed and refractory multiple myeloma (Raje N, et al. N Engl J Med 2019;380:1726-1737; Munshi NC, et al. J Clin Oncol 2020;38[suppl 15]. Abstract 8503), including those with high-risk (R-ISS stage III) relapsed refractory multiple myeloma (RRMM).”
In this video:
Dr. Saad Z. Usmani (Levine Cancer Institute, Charlotte, NC, USA) explains that in the population of heavily pretreated RRMM patients, when “there may be more bone marrow reserve, more healthy peripheral blood mononuclear cells, a less compromised immune status, and less extensive disease to debulk before cell therapy,” earlier use of ide-cel may result in improved outcomes versus standard therapies and offer an opportunity to replace transplant with CAR T-cell therapies.
Clinical trial information: NCT04196491
